Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MIF | P14174 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3197694 | 0.99 | MAPK14 (0.48) | MAPK14ADORA2AADORA1EGFRADORA3 | |
| SCHEMBL3193389 | 0.90 | ALDH1A1 (0.60) | MAPK14ADORA2AADORA1EGFRADORA3 | |
| SCHEMBL5379439 | 0.83 | MAPK14 (0.54) | MAPK14ADORA2AADORA1EGFRADORA3 | |
| SCHEMBL3208224 | 0.82 | LMNA (0.44) | MAPK14ADORA2AADORA1EGFRADORA3 | |
| SCHEMBL5392749 | 0.82 | EGFR (0.56) | MAPK14ADORA2AADORA1EGFRADORA3 | |
| SCHEMBL3194040 | 0.80 | EGFR (0.53) | MAPK14ADORA2AADORA1EGFRADORA3 | |
| SCHEMBL5389831 | 0.80 | EGFR (0.56) | MAPK14ADORA2AADORA1EGFRADORA3 | |
| SCHEMBL14744823 | 0.80 | EGFR (0.51) | MAPK14ADORA2AADORA1EGFRADORA3 | |
| SCHEMBL3210911 | 0.80 | EGFR (0.44) | MAPK14ADORA2AADORA1EGFRADORA3 | |
| SCHEMBL3187134 | 0.79 | KMT2A (0.66) | ADORA2AADORA1EGFRGSK3BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035920-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | AVIGEN, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100035920-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | AVIGEN, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20090318437-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | MEDICINOVA, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318437-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | MEDICINOVA, INC. | 2009-12-24 | — | — | US | disclosed |
| US-7585875-B2 | Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use | AVIGEN, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585875-B2 | Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use | AVIGEN, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080070912-A1 | Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use | AVIGEN, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2007146087-A2 | SUBSTITUTED PYRAZOLO [1,5-α] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | AVIGEN, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318437-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | PNPO, PDXK, CYP3A5 | MAPK14 1459/4885ADORA2A 236/4885ADORA1 422/4885 |
| US-20080070912-A1 | Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use | PNPO, PDXK, P2RX5 | MAPK14 1712/4885ADORA2A 214/4885ADORA1 361/4885 |
| US-20100035920-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | PNPO, PDXK, CYP3A5 | MAPK14 1459/4885ADORA2A 236/4885ADORA1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.